The key finding of the study: a particular protein fragment formed in active celiac disease forms nanosized structures, the so-called oligomers, and accumulates in a gut epithelial cell model
Combining cagrilintide with tirzepatide could theoretically produce 20-30% body weight loss by targeting three distinct pathways (GIP, GLP-1, and amylin), but the lack of clinical data means dosing protocols are speculative, side effect profiles unknown, and safety unclear
Your GP is the appropriate first point of contact and can assess your overall health, discuss evidence-based treatment options, and refer you to specialist services where appropriate
These symptoms should not be managed by lowering, skipping, or adding doses based on online advice
Hubermans Peptide Picks and Practical Guidance Dr